MA55021A - 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression - Google Patents

5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Info

Publication number
MA55021A
MA55021A MA055021A MA55021A MA55021A MA 55021 A MA55021 A MA 55021A MA 055021 A MA055021 A MA 055021A MA 55021 A MA55021 A MA 55021A MA 55021 A MA55021 A MA 55021A
Authority
MA
Morocco
Prior art keywords
dimethyltryptamine
dmt
meo
depression
methoxy
Prior art date
Application number
MA055021A
Other languages
English (en)
Other versions
MA55021B1 (fr
Inventor
Theis Terwey
Original Assignee
Gh Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gh Res Limited filed Critical Gh Res Limited
Publication of MA55021A publication Critical patent/MA55021A/fr
Publication of MA55021B1 publication Critical patent/MA55021B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA55021A 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure MA55021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22
PCT/EP2020/054803 WO2020169850A1 (fr) 2019-02-22 2020-02-24 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Publications (2)

Publication Number Publication Date
MA55021A true MA55021A (fr) 2021-12-29
MA55021B1 MA55021B1 (fr) 2024-05-31

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55021A MA55021B1 (fr) 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure

Country Status (32)

Country Link
US (2) US20220071958A1 (fr)
EP (3) EP3927337B8 (fr)
JP (2) JP7598326B2 (fr)
KR (1) KR20210154966A (fr)
CN (1) CN114555078A (fr)
AU (2) AU2020225410B2 (fr)
BR (1) BR112021016153A2 (fr)
CA (1) CA3130406A1 (fr)
CL (1) CL2021002174A1 (fr)
CO (1) CO2021010882A2 (fr)
CR (1) CR20210437A (fr)
DK (2) DK3927337T3 (fr)
DO (1) DOP2021000176A (fr)
EA (1) EA202192318A1 (fr)
EC (1) ECSP21060868A (fr)
ES (2) ES2984438T3 (fr)
FI (2) FI4349407T3 (fr)
HR (2) HRP20240532T1 (fr)
HU (2) HUE066828T2 (fr)
IL (1) IL285537A (fr)
LT (2) LT4349407T (fr)
MA (1) MA55021B1 (fr)
MD (1) MD3927337T2 (fr)
MX (2) MX2021009941A (fr)
NI (1) NI202100080A (fr)
PE (1) PE20220015A1 (fr)
PL (2) PL3927337T3 (fr)
PT (2) PT3927337T (fr)
RS (2) RS66912B1 (fr)
SI (2) SI3927337T1 (fr)
SM (1) SMT202400154T1 (fr)
WO (1) WO2020169850A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (fr) 2019-06-19 2020-12-23 GH Research Limited Récrystallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans de méthyl tert.-butyl éther (mtbe) sans ajouter un antisolvant
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
EP3868364A1 (fr) * 2020-02-24 2021-08-25 GH Research Limited Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine
WO2021226416A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matière et compositions pharmaceutiques
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
EP4192451A4 (fr) * 2020-08-05 2024-08-14 Universitätsspital Basel Procédé d'administration de dmt intraveineux pour psychothérapie assistée par dmt
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
JP7422474B2 (ja) * 2020-08-28 2024-01-26 サイビン ユーケー リミテッド 注射用製剤
EP4221682A2 (fr) * 2020-10-02 2023-08-09 Cybin IRL Limited Méthodes d'administration de médicaments psychédéliques par inhalation et systèmes de mise en oeuvre des méthodes
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (fr) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Méthode de traitement par alcaloïdes tryptamines
WO2022117640A1 (fr) * 2020-12-01 2022-06-09 Small Pharma Ltd Formulations inhalables
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3113414A1 (fr) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Protocole psychedelique pour systemes et methodes informatiques
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
JP2024517738A (ja) 2021-04-26 2024-04-23 アタイ セラピューティクス， インコーポレイテッド 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法
EP4329759A4 (fr) 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
JP2024517194A (ja) * 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
WO2022235927A1 (fr) * 2021-05-05 2022-11-10 Gilgamesh Pharmaceuticals, Inc. Nouvelles tryptamines et méthodes de traitement de troubles de l'humeur
CA3218110A1 (fr) 2021-05-25 2022-12-01 Majed Fawaz Nouveaux sels de n,n-dimethyltryptamine et nouvelles formes de sel cristallin
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (fr) 2021-09-30 2023-04-05 Biomind Labs Inc Nanoparticules encapsulées et nanoparticules de diméthyltriptamines
EP4433049A1 (fr) * 2021-11-18 2024-09-25 Cybin UK Ltd Formulations injectables et inhalables
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
WO2023129956A2 (fr) 2021-12-30 2023-07-06 ATAI Life Sciences AG Analogues de diméthyltryptamine utilisés en tant que médicaments d'administration d'oxyde nitrique
WO2023168023A1 (fr) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
WO2023186837A1 (fr) 2022-03-27 2023-10-05 GH Research Ireland Limited Traitement de la depression post-partum
IL315899A (en) 2022-03-27 2024-11-01 Gh Res Ireland Limited 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal
WO2023186834A1 (fr) 2022-03-27 2023-10-05 GH Research Ireland Limited Sel de bromhydrate cristallin de 5-meo-dmt
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
AU2023427992A1 (en) 2023-01-30 2025-09-18 GH Research Ireland Limited Treatment of mental disorders
AU2023427437A1 (en) 2023-01-30 2025-09-18 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
WO2024251807A1 (fr) * 2023-06-08 2024-12-12 Cybin Irl Limited Traitements d'animaux de compagnie
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025068714A1 (fr) * 2023-09-28 2025-04-03 Beckley Psytech Limited Compositions pharmaceutiques comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)
WO2025087962A1 (fr) 2023-10-23 2025-05-01 Reconnect Labs Ag Formulations pharmaceutiques comprenant du 5-meo-dmt et leurs utilisations thérapeutiques
WO2025111597A1 (fr) * 2023-11-22 2025-05-30 Gilgamesh Pharmaceuticals, Inc. Traitement de patients atteints de troubles de l'humeur à l'aide de n-éthyl-2-(5-fluoro-1h-indol-3-yl)-n-méthyléthan-1-amine ou d'un sel pharmaceutiquement acceptable de celle-ci
WO2026068951A1 (fr) * 2024-09-27 2026-04-02 Beckley Psytech Limited 5-méthoxy-dmt pour utilisation dans le traitement de la dépression
WO2026078143A1 (fr) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinaisons de 5-meo-dmt avec des antidépresseurs pour traiter la dépression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20040127409A1 (en) 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
ES2355983T3 (es) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG Balón de válvula para inhaladores .
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon

Also Published As

Publication number Publication date
AU2020225410A1 (en) 2021-08-19
EA202192318A1 (ru) 2021-12-21
PT3927337T (pt) 2024-05-17
EP4349407A3 (fr) 2024-07-03
HUE071841T2 (hu) 2025-09-28
EP4353314A2 (fr) 2024-04-17
PL4349407T3 (pl) 2025-07-21
ES3031965T3 (en) 2025-07-14
EP3927337B1 (fr) 2024-02-14
EP3927337A1 (fr) 2021-12-29
EP4349407B1 (fr) 2025-04-09
RS65706B1 (sr) 2024-08-30
LT4349407T (lt) 2025-07-10
MX2025002567A (es) 2025-04-02
CR20210437A (es) 2021-11-02
AU2026200720A1 (en) 2026-02-19
BR112021016153A2 (pt) 2021-10-05
NI202100080A (es) 2021-12-06
EP3927337B8 (fr) 2024-03-20
CO2021010882A2 (es) 2022-01-17
LT3927337T (lt) 2024-07-10
RS66912B1 (sr) 2025-07-31
KR20210154966A (ko) 2021-12-21
DK3927337T3 (da) 2024-04-22
PE20220015A1 (es) 2022-01-11
SI4349407T1 (sl) 2025-06-30
HRP20250590T1 (hr) 2025-07-04
EP4353314A3 (fr) 2024-07-03
IL285537A (en) 2021-09-30
DK4349407T3 (da) 2025-05-26
FI3927337T3 (fi) 2024-05-08
WO2020169850A1 (fr) 2020-08-27
US20220071958A1 (en) 2022-03-10
FI4349407T3 (fi) 2025-06-02
AU2020225410B2 (en) 2025-10-30
HRP20240532T1 (hr) 2024-07-19
HUE066828T2 (hu) 2024-09-28
ECSP21060868A (es) 2021-11-30
DOP2021000176A (es) 2021-11-21
MD3927337T2 (ro) 2024-08-31
CL2021002174A1 (es) 2022-01-28
MX2021009941A (es) 2021-12-10
CA3130406A1 (fr) 2020-08-27
EP4349407A2 (fr) 2024-04-10
JP7598326B2 (ja) 2024-12-11
CN114555078A (zh) 2022-05-27
US20240307350A1 (en) 2024-09-19
ES2984438T3 (es) 2024-10-29
MA55021B1 (fr) 2024-05-31
JP2022521337A (ja) 2022-04-06
SMT202400154T1 (it) 2024-07-09
SI3927337T1 (sl) 2024-07-31
JP2025029035A (ja) 2025-03-05
PT4349407T (pt) 2025-06-04
PL3927337T3 (pl) 2024-07-29

Similar Documents

Publication Publication Date Title
MA55021A (fr) 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
MA47719A (fr) Esketamine pour le traitement de la dépression
DK3927338T3 (da) Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
EP3908270A4 (fr) Combinaison de dextrométhorphane et de bupropion pour le traitement de la dépression
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
EP3946357A4 (fr) Formulations topiques pour le traitement de neuropathies périphériques
EP3749064A4 (fr) Machine de traitement au plasma
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3285795A4 (fr) Oligopeptides amers administrés par voie entérique pour le traitement du diabète de type 2
EP3405211A4 (fr) Octréotide par voie orale pour le traitement de maladies
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3634463A4 (fr) Protocole amélioré pour le traitement de la néphropathie lupique
EP3903725A4 (fr) Structure de jonction pour traitement
EP3813738A4 (fr) Revêtement nanofibreux pro-régénérateur pro-réparateur pour implants médicaux
EP3472320A4 (fr) Dysferline tronquée pour le traitement de la dysferlinopathie
MA55531A (fr) Procédés pour le traitement de béta-thalassémie
EP3953485A4 (fr) Modulation de htra1 pour le traitement de la dmla
MA42419A (fr) Méthode de traitement de l'encéphalopathie hépatique
EP3960307A4 (fr) Liquide de traitement
EP3630289A4 (fr) Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies
EP3324993A4 (fr) Composition pour le traitement du vrs
EP3886831A4 (fr) Compositions permettant le traitement de la symphysiolyse